Research programme: nausea and vomiting therapeutics - Solvay
Alternative Names: SLV 323Latest Information Update: 10 Jul 2007
At a glance
- Originator Solvay Pharmaceuticals
- Class
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Nausea and vomiting
Most Recent Events
- 25 Nov 2003 Preclinical trials in Nausea and vomiting in Belgium (unspecified route)